Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Biocon Ltd. has launched its drug-device combination for diabetes and obesity, Diavorin and Vobexoryn respectively, in the Netherlands via Pharmamedic BV.

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

If you have ever wondered whether Regeneron Pharmaceuticals is a smart buy at around $718 a share, you are not alone; investors are trying to figure out if the current price really reflects its long ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...

Fractyl Health Inc. is giving a peek at how its treatment to help patients coming off of GLP-1 drugs maintain their weight ...